BNP Paribas Financial Markets
CRSP icon

BNP Paribas Financial Markets’s CRISPR Therapeutics CRSP Stock Holding History

BNP Paribas Financial Markets’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.34M Sell
24,577
-4,522
-16% -$238K ﹤0.01% 3113
2026
Q1 		$1.38M Buy
29,099
+2,112
+8% +$111K ﹤0.01% 2913
2025
Q4 		$1.42M Buy
26,987
+1,961
+8% +$117K ﹤0.01% 2876
2025
Q3 		$1.62M Buy
25,026
+5,769
+30% +$331K ﹤0.01% 2767
2025
Q2 		$937K Buy
19,257
+842
+5% +$32.6K ﹤0.01% 2947
2025
Q1 		$627K Sell
18,415
-64,579
-78% -$2.74M ﹤0.01% 3052
2024
Q4 		$3.27M Sell
82,994
-4,962
-6% -$234K ﹤0.01% 2062
2024
Q3 		$4.13M Sell
87,956
-48,377
-35% -$2.45M ﹤0.01% 1615
2024
Q2 		$7.36M Sell
136,333
-12,609
-8% -$729K 0.01% 1234
2024
Q1 		$10.2M Buy
148,942
+106,652
+252% +$7.63M 0.01% 1082
2023
Q4 		$2.65M Sell
42,290
-87,212
-67% -$4.82M ﹤0.01% 1785
2023
Q3 		$5.88M Buy
129,502
+76,675
+145% +$3.96M 0.01% 1167
2023
Q2 		$2.97M Buy
52,827
+5,150
+11% +$292K ﹤0.01% 1528
2023
Q1 		$2.16M Sell
47,677
-42,591
-47% -$2.07M ﹤0.01% 1767
2022
Q4 		$3.67M Buy
90,268
+29,143
+48% +$1.55M 0.01% 1469
2022
Q3 		$3.99M Buy
61,125
+55,656
+1,018% +$4.03M 0.01% 1485
2022
Q2 		$332K Sell
5,469
-16,424
-75% -$966K ﹤0.01% 2870
2022
Q1 		$1.37M Sell
21,893
-3,611
-14% -$227K ﹤0.01% 2096
2021
Q4 		$1.93M Buy
25,504
+24,331
+2,074% +$2.13M ﹤0.01% 2057
2021
Q3 		$131K Buy
1,173
+13
+1% +$1.63K ﹤0.01% 3181
2021
Q2 		$188K Buy
1,160
+569
+96% +$69.2K ﹤0.01% 2882
2021
Q1 		$72K Sell
591
-14,056
-96% -$2.12M ﹤0.01% 3494
2020
Q4 		$2.24M Buy
14,647
+7,514
+105% +$888K ﹤0.01% 1571
2020
Q3 		$597K Buy
7,133
+808
+13% +$71.7K ﹤0.01% 2110
2020
Q2 		$465K Sell
6,325
-32,029
-84% -$1.87M ﹤0.01% 2133
2020
Q1 		$1.63M Buy
38,354
+37,149
+3,083% +$1.92M ﹤0.01% 1607
2019
Q4 		$73.4K Sell
1,205
-23,577
-95% -$1.29M ﹤0.01% 3445
2019
Q3 		$1.02M Buy
24,782
+23,911
+2,745% +$1.14M ﹤0.01% 1827
2019
Q2 		$41K Buy
+871
New +$34.8K ﹤0.01% 3540

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

BNP Paribas Financial Markets's CRSP Position: Q2 2026 in Review

BNP Paribas Financial Markets reduced its CRISPR Therapeutics (CRSP) stake by 16% in Q2 2026, selling an estimated $238K and leaving 24,577 shares worth $1.34M. The position accounts for ﹤0.01% of the portfolio, ranked #3113.

BNP Paribas Financial Markets first reported a position in CRSP in Q2 2019 and has held it in 29 quarters since. The position peaked at $10.2M in Q1 2024. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • BNP Paribas Financial Markets held 24,577 shares of CRISPR Therapeutics worth $1.34M as of Q2 2026.
  • BNP Paribas Financial Markets sold 4,522 CRISPR Therapeutics shares in Q2 2026, an estimated $238K.
  • CRISPR Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #3113 holding.
  • BNP Paribas Financial Markets first reported a position in CRISPR Therapeutics in Q2 2019 and has held it in 29 quarters since.
  • BNP Paribas Financial Markets's CRISPR Therapeutics position peaked at $10.2M in Q1 2024.
  • 524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.